FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

49

Washington,	D.C.	2054

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-0287									
	Estimated average burden									
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Meng Lei					2. Issuer Name and Ticker or Trading Symbol Dianthus Therapeutics, Inc. /DE/ [DNTH]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 09/11/2023									Officer (give title below)		Other (specify below)		
C/O DIA	C/O DIANTHUS THERAPEUTICS, INC. 4. If Am					If Am	If Amendment, Date of Original Filed (Month/Day/Year)							6.	Individual	or Joint/Group	Filing (Check	Applicable
7 TIMES SQUARE, 43RD FLOOR						Line) Form filed by One Repor										e Reporting Per	rson	
(Street) NEW YORK NY 10036													y Fo	rm filed by Mor erson		I		
					_ R	ule	10b5	5-1(c) Tran	sac	ction In	dicatio	n					
(City) (State) (Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Ta	ble I - Nor	า-Der	rivativ	/e S	ecuriti	ies A	Acquire	d, Di	isposed	l of, or	Bene	eficia	lly Owr	ied		
Date			nsactio		2A. Deemed Execution Date, if any (Month/Day/Year		Cod	Transaction Dispo		ecurities Acquired (A) o posed Of (D) (Instr. 3, 4 a					6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Cod	e V	Amou	nt (/	A) or O)	Price	Tran	saction(s) r. 3 and 4)		(11150.4)	
			Table II -	Deriv (e.g.,	ative puts	Sec , cal	curitie Ils, wa	s Ad rran	cquired, its, opti	Dis ons,	posed o	of, or B rtible se	enef ecuri	iciall ties)	y Owne	d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ate,	4. Transaction Code (Instr. 8)		of Ex		Expiratio	te Exercisable and ration Date th/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		urity	8. Price o Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nui of	ount mber ares				
Stock Option (Right to Buy)	\$11.2	09/11/2023			A		6,500		(1)	C	09/10/2033	Commor Stock	6,	500	\$0	6,500	I	See footnote ⁽²⁾ (3)(4)
1. Name a Meng		f Reporting Person*										•				•		•
		(First) HERAPEUTICS , 43RD FLOOR	(Middl	e)														
(Street) NEW Y	ORK	NY	10030	6														
(City)		(State)	(Zip)															
		f Reporting Person* Management																
(Last) 2828 N	HARWOO!	(First) D STREET, SUI	(Middl	e)														
(Street) DALLA	S	TX	7520	1														
(City)		(State)	(Zip)															

- 1. This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer.
- 2. Under Ms. Meng's arrangement with Avidity Partners Management LP (the "Avidity"), Ms. Meng holds the option for the benefit of clients of Avidity. Ms. Meng is obligated to turn over to the Avidity any net cash or stock received from the option for the benefit of Avidity. Ms. Meng is obligated to turn over to the Avidity any net cash or stock received from the option for the benefit of Avidity. Ms. Meng therefore disclaims beneficial ownership of the option and underlying common stock. The reported shares may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC. Under Ms. Meng's arrangement with Avidity Partners Management LP (the "Avidity"), Ms. Meng holds the option for the benefit of clients of
- 3. Ms. Meng is obligated to turn over to the Avidity any net cash or stock received from the option for the benefit of Avidity. Ms. Meng therefore disclaims beneficial ownership of the option and underlying common stock. The reported shares may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC.

MENG LEI, /s/ Adam Veness,

as attorney-in-fact for Lei Meng 09/13/20

AVIDITY PARTNERS

MANAGEMENT LP, By:

Avidity Partners Management

(GP) LLC, its general partner, 09/13/2023

/s/ David Witzke Managing

<u>Member, /s/ Michael Gregory</u> <u>Managing Member</u>

AVIDITY PARTNERS

MANAGEMENT (GP) LLC, /s/

David Witzke Managing 09/13/2023

Member, /s/ Michael Gregory

Managing Member

DAVID WITZKE, /s/ David 09/13/2023

<u>Witzke</u>

MICHAEL GREGORY, /s/
09/13/2023

Michael Gregory

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).